After two straight days of sell-offs, the major indexes waffled on Wall Street Tuesday. Axios Business Editor Dan Primack explains the factors potentially driving this market volatility.
Disney stock rose after they beat on earnings per share. Chipotle also reported and beat on both revenue and earnings per share. Cheddar breaks down the earnings reports from both companies.
Snap beat on both revenue and earnings per share, marking one of its best earning reports to date. In after hours, Snap shares rocketed up as user growth was reported as an increase.
Recreational marijuana has been legal in California since January 1 and since then cannabis stores like MedMen in West Hollywood have been a significant bump in sales and foot traffic. Alyssa Julya Smith visited the MedMen location in West Hollywood one month after the store first started selling recreational marijuana.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
ReturnPro CEO Sender Shamiss to discuss how his company is changing the way we make returns and how Trump's tariffs are affecting the return business. Watch!
Chris Beauchamp, Chief Market Analyst at IG International, joins J.D. Durkin to give analysis on the recent trade truce between the U.S. and China. Watch!
Shan Aggarwal, VP of Corporate and Business Development at Coinbase, discusses the company's acquisitio of Deribit as it heads into the S&P 500. Watch!
Shopping expert Trae Bodge discusses how talks between the U.S. and China is good news for now, but uncertainty remains for back-to-school and the holidays.
Jake Traylor, White House reporter at Politico, joins Cheddar to discuss how Trump is aiming to lower drug prices and how it differs from Biden's approach.
